Skin toxicity, or folliculitis, is the most common adverse side effect resulting from the use of antineoplastic signal transduction inhibitors like the epidermal growth factor receptor inhibitors (EGFRI) panitumumab and poziotinib. This condition takes a toll on a patient’s quality of life and can affect up to 90% of patients. Moreover, it is one of the primary contributing factors to the patient’s decision to discontinue antineoplastic therapy, thus highlighting the need for better dermatologic interventions to help mitigate the side effects resulting from EGFRI treatment. We present the case of a 76-year-old female patient who presented with a sudden, severe folliculitis exclusively affecting her scalp following years of stable tumor suppressor therapy